Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

41 patients with radiographically verified degenerative joint disease of the hand who had at least one acutely inflamed Heberden node entered into the study. 22 patients were treated with 300 mg N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) per day for 4 weeks and 19 patients received placebo. Measures of efficacy were: the number of painful joints on both hands, an index of pain, the number of inflamed Heberden nodes and the grip strength (mmHg). Disease activity was similar in both groups at the beginning of the study. Analyses after one week of treatment and at the last observation at the conclusion of the study revealed significant differences in favor of meclofenamate sodium. This indicates that meclofenamate sodium treatment of degenerative joint disease of the hands is significantly superior to placebo. The reduction of the number of inflamed Heberden nodes demonstrates the anti-inflammatory effect of meclofenamate sodium, while the reduction of painful joints and the decreased pain index is evidence of the analgesic effect of this drug. The increase in grip strength indicates an improvement of function. The results further demonstrate the early onset of treatment effect with meclofenamate sodium. Meclofenamate sodium was well tolerated.
 ...
PMID:Meclofenamate sodium in the treatment of degenerative joint disease of the hand (Heberden nodes). 634 52

130 patients with edema as the sequel of a traumatic incident were selected for this study, 43 patients were treated with 300 mg N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) per day for one week, 44 patients received 600 mg oxyphenbutazone per day and 43 patients received placebo. Medication could be terminated if edema and pain disappeared or if deterioration or intolerance occurred. Extent of edema and degree of pain were assessed at entry into the study and on days 3, 5 and 8. Efficacy was assessed by the number of days elapsed before definite reduction and/or complete disappearance of edema and by the decrease and disappearance of pain. Meclofenamate sodium proved to be significantly superior to placebo in the treatment of patients with post-traumatic edema and post-traumatic pain. Reduction and disappearance of edema and cessation of pain occurred significantly more promptly in patients receiving meclofenamate sodium than in those receiving placebo. Although no statistically significant differences were observed between meclofenamate sodium and oxyphenbutazone, the results suggested that meclofenamate sodium might be clinically superior. Meclofenamate sodium was well tolerated.
 ...
PMID:Meclofenamate sodium in the treatment of post-traumatic edema. Report of a controlled double-blind study. 634 54


<< Previous 1 2